Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Soluble Aspirin Could Be Groundbreaking Treatment For Glioblastoma



Previous research has suggested that aspirin has anti-cancer properties, however currently-available liquid forms of the drug are not fully soluble.

Share this!

Tweet: Blood-brain barrier allows some molecules to pass into the brain http://ctt.ec/60spe+Blood-brain barrier allows some molecules to pass into the brain.

Tweet: Soluble #aspirin ten times more effective at treating #glioblastoma  http://ctt.ec/K8UT2+Soluble aspirin ten times more effective at treating glioblastoma.

July 4, 2016 | by Sarah Massey, M.Sc.

A new truly-soluble drug containing liquid aspirin, could offer a valuable treatment option for patients with a type of brain tumor known as glioblastoma. Researchers from the Brain Tumour Research Centre of Excellence at the University of Portsmouth in the United Kingdom, found that the soluble drug was able to cross the blood-brain barrier.

The blood-brain barrier is a semi-permeable membrane, which allows certain molecules to pass through, while preventing pathogens and other foreign substances from entering the brain. While this membrane is integral to protect the brain, cancer drug developers have faced numerous challenges in designing therapies that are able to pass through the barrier.

Many cancer drugs used to fight tumors in other parts of the body are too large to fit through the blood-brain barrier. Previous research has suggested that aspirin has anti-cancer properties, however currently-available liquid forms of the drug are not fully soluble. Instead, these drugs contain small particles of solid aspirin which can cause gastric side effects when taken orally.

In collaboration with Innovate Pharmaceuticals, the University of Portsmouth researchers developed the soluble drug, named IP1867B, which contains aspirin along with two other compounds. These ingredients have been show to destroy cancer cells without damaging the surrounding healthy brain tissue, and all three compounds have already been approved for clinical use.

In testing the drug on tumor cells and tissue collected from adults and children with brain cancer, the researchers found that IP1867B was ten times more effective at treating glioblastoma compared to any combination of currently-available treatments for the cancer. Glioblastoma is one of the most common and deadly forms of brain cancer in adults.

“This is a potential game-changer for research into brain tumours and clearly shows what sustainable research is able to achieve,” said Sue Farrington Smith, chief executive of Brain Tumour Research. “It is science like this that will enable us to eventually find a cure for this devastating disease which kills more children and adults under the age of 40 than any other cancer.” The researchers say that further preclinical development must be done before the soluble aspirin can enter early-stage clinical trials involving humans.

Keywords: Aspirin, Gioblastoma, Drug Delivery


Share this with your colleagues!

New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer

March 29, 2017 - The US Food and Drug Administration (FDA) has approved Zejula (niraparib) as a maintenance treatment for women with certain types of recurrent cancers, including epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Featured In: Pharmaceutical News

Nektar’s Opioid Analgesic Meets Endpoints in Phase III Clinical Trial

March 28, 2017 - Nektar Therapeutics has announced that their opioid analgesic has met both its primary and secondary endpoint in a recent Phase III efficacy study.

Featured In: Clinical Trials News

Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?


Strategies for Deploying Innovative Solutions for Perimeter Security

Natural History vs. Registry Studies in Rare Disease

The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act

Copyright © 2016-2017 Honeycomb Worldwide Inc.